Compare PBI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBI | IMCR |
|---|---|---|
| Founded | 1920 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | PBI | IMCR |
|---|---|---|
| Price | $10.78 | $31.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $11.67 | ★ $64.30 |
| AVG Volume (30 Days) | ★ 1.6M | 542.6K |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,931,125,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.49 |
| Revenue Next Year | N/A | $11.05 |
| P/E Ratio | $23.59 | ★ N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $7.40 | $23.15 |
| 52 Week High | $13.11 | $40.72 |
| Indicator | PBI | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 35.90 |
| Support Level | $10.25 | $30.60 |
| Resistance Level | $10.76 | $33.49 |
| Average True Range (ATR) | 0.25 | 1.51 |
| MACD | 0.03 | -0.23 |
| Stochastic Oscillator | 91.26 | 14.02 |
Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.